PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31

PUMA BIOTECHNOLOGY, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$10.21+0.38 (+3.87%)

Close on Oct 19, 2026

Market cap: $537.01M
P/E (TTM): 19.6
Dividend yield: –

Earnings

Next report expected Nov 5, 2026, after market close (estimated from past report dates)

Quarter	Reported	Time	Revenue	EPS (GAAP)	EPS (adjusted)
Q2 FY2026 Ended Jun 30, 2026	Aug 6, 2026	After market close	$56.50M	$0.16	$0.19
Q1 FY2026 Ended Mar 31, 2026	May 7, 2026	After market close	$44.80M	$-0.07	$-0.04
Q4 FY2025 Ended Dec 31, 2025	Feb 26, 2026	After market close	$75.50M	$0.26	$0.29
Q3 FY2025 Ended Sep 30, 2025	Nov 6, 2025	After market close	$54.50M	–	–
Q2 FY2025 Ended Jun 30, 2025	Aug 7, 2025	After market close	$52.40M	$0.12	$0.15
Q1 FY2025 Ended Mar 31, 2025	May 8, 2025	After market close	$46.00M	$0.06	$0.10
Q4 FY2024 Ended Dec 31, 2024	Feb 27, 2025	After market close	$59.10M	$0.39	$0.43
Q3 FY2024 Ended Sep 30, 2024	Nov 7, 2024	After market close	$80.50M	–	–
Q2 FY2024 Ended Jun 30, 2024	Aug 1, 2024	After market close	–	–	–
Q1 FY2024 Ended Mar 31, 2024	May 2, 2024	After market close	–	–	–
Q4 FY2023 Ended Dec 31, 2023	Feb 29, 2024	After market close	–	–	–

Company guidance

Outlook given with results on Aug 6, 2026, compared with the previous outlook

Measure	Period	Guidance	vs. prior
Gross to Net Adjustment	New Full Year 2026	26.5% to 27.5%	Lowered
Net Product Revenue	New Full Year 2026	$205.00M to $209.00M	Raised
Royalty Revenue	New Full Year 2026	$19.00M to $22.00M	Lowered
Net Income	New Full Year 2026	$17.00M to $20.00M	Lowered
Gross to Net Adjustment	Third Quarter 2026	26% to 27%	New
Net Product Revenue	Third Quarter 2026	$54.00M to $56.00M	New
Royalty Revenue	Third Quarter 2026	$2.00M to $3.00M	Lowered
Net Income	Third Quarter 2026	$2.00M to $3.50M	Raised
Total Revenue	New Full Year 2026	$224.00M to $231.00M	Raised
Total Revenue	Third Quarter 2026	$56.00M to $59.00M	New

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Puma Biotechnology filed with the SEC

Aug 6, 2026, 4:19 PM ET
Puma Biotechnology Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
May 7, 2026, 4:32 PM ET
Puma Biotechnology Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Feb 26, 2026, 4:16 PM ET
Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Nov 6, 2025, 4:16 PM ET
Puma Biotechnology Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aug 7, 2025, 4:32 PM ET
Puma Biotechnology Reports Second Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
May 8, 2025, 4:20 PM ET
Puma Biotechnology Reports First Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Feb 27, 2025, 4:22 PM ET
Puma Biotechnology Reports Fourth Quarter and Full Year 2024
Results of operations · EX-99.1 to Form 8-K
Nov 7, 2024, 4:14 PM ET
Puma Biotechnology Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aug 1, 2024, 4:17 PM ET
Puma Biotechnology Reports Second Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
May 2, 2024, 4:18 PM ET
Puma Biotechnology Reports First Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Feb 29, 2024, 4:16 PM ET
Puma Biotechnology Reports Fourth Quarter and Full Year
Results of operations · EX-99.1 to Form 8-K
Jan 18, 2024, 9:00 AM ET
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Nov 2, 2023, 4:19 PM ET
Puma Biotechnology Reports Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aug 3, 2023, 4:12 PM ET
Puma Biotechnology Reports Second Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
May 4, 2023, 4:16 PM ET
Puma Biotechnology Reports First Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Mar 2, 2023, 4:11 PM ET
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Results of operations · EX-99.1 to Form 8-K
Jan 9, 2023, 9:16 AM ET
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Dec 9, 2022, 8:34 AM ET
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Dec 7, 2022, 7:45 PM ET
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Dec 7, 2022, 7:45 PM ET
Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial at the 2022 San Antonio Breast Cancer Symposium
Regulation FD disclosure · EX-99.2 to Form 8-K
Nov 10, 2022, 4:30 PM ET
WHEREAS, on February 2, 2016, Eshelman filed a lawsuit captioned Eshelman v. Puma Biotechnology, Inc. , Case No. 7:16-cv-00018-D (E.D.N.C.) (the “ Lawsuit ”);
Other events · EX-99.1 to Form 8-K
Nov 3, 2022, 4:11 PM ET
Puma Biotechnology Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Aug 4, 2022, 4:18 PM ET
Puma Biotechnology Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
May 5, 2022, 4:15 PM ET
Puma Biotechnology Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Mar 14, 2022, 4:15 PM ET
Puma Biotechnology Announces $10 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Mar 3, 2022, 4:14 PM ET
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
Results of operations · EX-99.1 to Form 8-K
Jan 10, 2022, 7:04 AM ET
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Nov 4, 2021, 4:17 PM ET
Puma Biotechnology Reports Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K

Where these numbers come from

Parsed from the XBRL in Puma Biotechnology's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PBYI.

Revenue growth-2.9% · median 222.7%

Operating margin13.2% · median -81.0%

Net margin11.6% · median -87.5%

Company	Revenue	Growth
RIGL	$276.79M	+3.3%
SNDX	$252.25M	+222.7%
IDYA	$234.13M	–
PBYI	$231.24M	-2.9%
NUVB	$169.90M	+1083.6%
VSTM	$87.53M	–

Company

Next earnings (est.): Nov 5, 2026, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 179
Held by institutions: 74.9%
Auditor: KPMG LLP
SEC CIK: 1401667

Advertisement
300 × 250